Bausch Health Companies Inc (BHC) — Analysis Summary
Bausch Health Companies Inc (BHC) has a market cap of $1.81B with year-over-year revenue growth of +6.7%. Net margin stands at 1.5%. The stock trades at a P/E ratio of -1.5.
Key Takeaways
- Revenue changed +6.7% year-over-year
- Net margin of 1.5%
- P/E ratio of -1.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, BHC posted revenue growth of +6.7% and trades at a P/E of -1.5.
Bausch Health Companies Inc (BHC)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 11.6x — highly leveraged, potential refinancing risk
Interest coverage at 0.4x — earnings do not cover interest payments
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
20,300
Headquarters
QUEBEC, A8
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.